BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GlaxoSmithKline (GSK) Drug Fails to Hit Goal in Breast Cancer Trial


12/9/2011 8:19:10 AM

GlaxoSmithKline has suffered a setback with the news that Tykerb has failed a late-stage study investigating whether adjuvant treatment with the drug will improve disease-free survival in women with early-stage HER2 positive breast cancer. Results have been presented at the San Antonio Breast Cancer Symposium from TEACH, a Phase III trial designed to evaluate the effects of Tykerb/Tyverb (lapatinib) monotherapy when given to women who were diagnosed with HER2 positive breast cancer, had received treatment, but not Roche's rival drug Herceptin (trastuzumab), and remained disease free. The primary objective of the study, which involved over 3,000 women, was to compare DFS between women receiving lapatinib and those receiving placebo.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES